olfactory receptor family 7 subfamily E member 22 pseudogeneGenealiases: OR3.6 · OR6DG
Q-omics provides the consensus-scored OR7E22P profile across patient tissues and cancer cell-line models. OR7E22P expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, OR7E22P is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, OR7E22P RNA expression shows 11,912 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, KIRC, and TGCT as cancer lineages where OR7E22P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR7E22P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR7E22P survival associations across molecular data types. OR7E22P RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR7E22P RNA expression–survival associations across cancer types. High OR7E22P expression shows unfavorable associations in ACC, KICH, LIHC, COAD and KIRP, but favorable associations in UVM. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for OR7E22P RNA expression.
This table summarizes OR7E22P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for OR7E22P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR7E22P shows lower tumor expression in KIRC, BRCA and KICH and higher tumor expression in THCA, UCEC and LUAD. The KIRC box plot shows higher OR7E22P RNA expression in normal versus tumor tissue (log2 FC = −0.102, t-test p < 0.001).
This table shows molecular features associated with OR7E22P in patient tissues and cancer cell lines. In patient samples, OR7E22P shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
